- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04855630
Combatendo a doença de Alzheimer através do sono e do exercício (CASE)
Combatendo a doença de Alzheimer através do sono e do exercício (CASE)
The Combating Alzheimer's through Sleep and Exercise (CASE) study is an exploratory, hypothesis-generating trial designed to: (1) assess whether improvements in sleep are associated with improvements in cognitive performance and cardiovascular and metabolic health; (2) evaluate the effects of structured, moderate-level aerobic and anaerobic exercise on cognitive performance and cardiovascular and metabolic health; (3) examine the combined, potentially synergistic effects of both interventions on cognitive performance and cardiovascular and metabolic health; and (4) investigate the role of light exposure as a potential modulator of sleep parameters.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Azizi A Seixas, PhD
- Número de telefone: 3052431301
- E-mail: Azizi.seixas@med.miami.edu
Estude backup de contato
- Nome: Debbie Chung, PhD
- Número de telefone: 3052431301
- E-mail: dxc1729@miami.edu
Locais de estudo
-
-
Florida
-
Miami, Florida, Estados Unidos, 33136
- Recrutamento
- University of Miami Hospitals
-
Contato:
- Azizi A Seixas, PhD
- Número de telefone: 3052431301
- E-mail: Azizi.seixas@med.miami.edu
-
Investigador principal:
- Azizi A Seixas, PhD
-
Subinvestigador:
- Alberto Ramos, MD
-
Contato:
- Debbie Chung, PhD
- Número de telefone: 3052431301
- E-mail: dxc1729@miami.edu
-
Subinvestigador:
- Debbie Chung, PhD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Aged 55-80 years at the time of the screening visit
- Able to ambulate safely and independently
- Able to safely perform moderate-intensity exercise as per the Physical Activity Readiness Questionnaire (PAR-Q, a validated exercise readiness questionnaire)
- Able to wear and use Fitbit wristwatch and/or the Elemind Neuromodulation headband and Lys devices
- Able to operate a digital device like mobile phone or computer
- Able and willing to provide venous blood samples
- Able to understand and speak English (our AR-based MCI diagnosis tool does not yet have capacity for other languages)
- Able to self-report a history of cognitive changes or impairment
- Be cognitively able (including those with and without MCI) and willing to provide informed consent
- Body weight <400 pounds (<181.4kg) in order to safely operate the NuStep T4r Recumbent Stepper stationary bicycle
Exclusion Criteria:
- Severe mobility limitations that prevent safe participation in moderate exercise protocols
- Unstable or uncontrolled medical conditions (e.g., recent cardiovascular event (<6 months), cerebrovascular accident or transient ischemic attack (<6 months), active cancer, or uncontrolled diabetes) that pose safety concerns
- Inability to complete intake screening procedures
- Severe uncorrected hearing impairment-particularly if it precludes effective utilization of the Elemind Neuromodulation headband-and/or vision impairment that interferes with digital device usage or in-person exercise guidance
- Determined to have Alzheimer's/dementia based on performance on the Quick Mild Cognitive Impairment (QMCI).
- Inability or unwillingness to learn or engage with digital devices (e.g., smartphone, Fitbit, Elemind, or Lys), even with staff support
- Regular pre-study engagement in ≥150 minutes of moderate-level and/or ≥75 minutes of vigorous-level exercise per week based on Fitbit data obtained during the initial seven-day onboarding screening period
- Determined to have sufficient sleep, as defined by a sleep efficiency mean of ≥80%) based on Elemind Neuromodulation headband data obtained during the initial seven-day onboarding screening period
- Current usage of disease-modifying therapy targeting amyloid (e.g., anti-amyloid monoclonal antibodies) or tau
- Body weight ≥400 pounds (≥181.4kg), which would pose a safety risk during the operation of the NuStep recumbent stationary bicycle
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Sleep Only Group
Participants in this group will wear the Elemind headband 3-4 times weekly for 8 weeks. |
The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm. |
|
Comparador Ativo: Exercise Only Group
Participants in this group will participate in a structured, on-site, twice a week exercise program for 60 minutes/session for 8 weeks (16 total sessions). Each exercise session is comprised of 60 minutes, including 10 minutes of warm-up, 20 minutes of cardiovascular exercise on a stationary bike, 20 minutes of resistance training (1 day of upper body focus, 1 day of lower body focus each week), and 10 minutes of cooling off). |
Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks. |
|
Comparador Ativo: Exercise and Sleep Group
Participants in this group will take part in the on-site, structured exercise program twice per week for 8 weeks in additional to wearing the Elemind headband 3-4 times per week for 8 weeks. |
The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm. Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Glycated Hemoglobin (HbA1c) Levels
Prazo: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Total Cholesterol Levels
Prazo: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Triglycerides Levels
Prazo: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
High-sensitivity C-reactive protein (hs-CRP) Levels
Prazo: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Low-Density Lipoprotein (LDL) Levels
Prazo: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
C-Peptides
Prazo: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
High-Density Lipoprotein (HDL) Levels
Prazo: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Cognitive Function
Prazo: Up to 8 weeks
|
Cognitive function gauged from Altoida's Digital Neuro-Signatures |
Up to 8 weeks
|
|
Insulin Levels
Prazo: Up to 8 weeks
|
Measured from blood sample |
Up to 8 weeks
|
|
Neurofilament light chain
Prazo: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Total Sleep Duration
Prazo: Up to Week 8
|
Measured from Elemind |
Up to Week 8
|
|
Slow Wave Sleep Duration
Prazo: Up to Week 8
|
Measured from Elemind |
Up to Week 8
|
|
%Slow-wave Sleep
Prazo: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Rapid Eye Movement Duration
Prazo: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
%REM
Prazo: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Light Non-Rapid Eye Movement Duration
Prazo: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
%Light Non-Rapid Eye Movement Sleep
Prazo: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Sleep Efficiency
Prazo: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Sleep Onset Latency
Prazo: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Restlessness (Restless Bouts/Hour during Sleep)
Prazo: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Light Exposure
Prazo: Up to Week 8
|
Measured by LYS Device |
Up to Week 8
|
|
Psychosocial Metrics
Prazo: Up to Week 8
|
Measured by Questionnaires |
Up to Week 8
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Azizi A Seixas, PhD, University of Miami
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 20220931
- 20-01023 (Outro identificador: NYU)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .